Onartuzumab companion diagnostic - Ventana Medical SystemsAlternative Names: CONFIRM anti-total cMET; MetMAb IHC; Roche cMET assay; VENTANA cMET assay; Ventana's cMET IHC test
Latest Information Update: 29 Jan 2015
At a glance
- Originator Ventana Medical Systems
- Class Monoclonal antibody diagnostics
- Mechanism of Action Diagnostic imaging enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Non-small cell lung cancer